Primary Navigation
Want to create or adapt books like this? Learn more about how Pressbooks supports open publishing practices.
Book Contents Navigation
Introduction
1. 1.1 An Introduction to Lung Cancer and Lung Cancer Research
2. 1.1 Apoptosis & Cancer
3. 1.1 Lung Cancer
4. 1.1 Treatments for Lung Cancer
5. 1.1 Cells Used for Research
6. 1.1 Review of Section 1.1
7. 1.2 Cell Culture and Treatment
8. 1.2 Cell Apoptosis and Viability
9. 1.2 Vitexin and the Mitochondria
10. 1.2 Western Blot and the mTOR Pathway
11. 1.2 Tumour Formation Assay
12. 1.2 Review of Section 1.2
13. 1.3 Conclusion and Discussion
14. 1.3 Vitexin: A Promising Anti-Tumour Treatment?
15. 1.3 Critical Analysis
16. 1.3 Future Directions
17. 1.4 Review of Chapter 1 Quiz
18. Chapter 3: Acknowledgements
19. 3.1 What is Multiple Sclerosis?
20. 3.2 Role of the Immune System in Multiple Sclerosis
21. 3.3 EAE Murine Model and the Microbiome
22. 3.4 Diet Selection for Reduction of MS Symptoms
23. 3.5 Diet-Associated Modifications of the Microbiota
24. 3.6 Immune Parameters
25. 3.7 Modulation of Disease Activity
26. 3.8 What have we learned?
27. References
28. 2.1: Background of Alzheimer's Disease
29. 2.2 Long Term Potentiation
30. 2.3: Amyloid-β Role in Alzheimer's Disease
31. 2.4: Synaptic Dysfunction in Alzheimer's Disease
32. 2.5: Whole-Cell Patch Clamp Technique
33. 2.6: Endophilin A
34. 2.7: Endophilin-1 Knockdown
35. 2.8: Future Directions
36. 2.9: Test Yourself!
37. Citations
38. Visual References
39. Authors
40. Chapter Overview
41. 4.1 Introduction
42. 4.2 Current Treatments and Limitations
43. 4.3 The Use of rHC in Myocardial Infarction
44. 4.4 The Efficacy of Recombinant Human Collagen
45. 4.5 Future Directions
46. 4.6 Chapter Review
47. 4.7 References
48. 6.1 Overview of Chronic Kidney Disease (CKD)
49. 6.2 Mechanism of Atorvastatin on Cholesterol Biosynthesis
50. 6.3 The Use of Atorvastatin on Chronic Kidney Disease (CKD) Patients
51. 6.4 Results of Atorvastatin Treatment for CKD Patients
52. 6.5 Critical Analysis: Limitations of Statin Drug Trials
53. 6.6 Future Directions: Atorvastatin combination therapy
54. 6.7 References
55. 5.1: Introduction
56. 5.2: The Process: Preparation and Imaging
57. 5.3: The Role of Calcium
58. 5.4: Inhibited Autophagic Flux
59. 5.5: Mitophagy and Altered Mitochondrial Dynamics
60. 5.6: Mitochondrial Swelling and Stress-Induced Mitochondrial Hyperfusion
61. 5.7: Mitochondrial Superoxide Levels and Protein Oxidation
62. 5.8: Altered Mitochondrial Membrane Potential
63. 5.9: Aggregation of Mitochondrial Nucleoids and mtDNA Damage
64. 5.10: Role of Nicotine
65. 5.11: Significance in Health and Disease
66. 5.12: Critical and Comparative Analyses
67. 5.13: Future Directions
68. 5.14: Conclusion
69. Concept Check
70. References Cited
71. How to use Imgur to bypass Pressbook's image cap
7.1 - Overview of Alzheimer's Disease
7.1.1 - Cell and Molecular Hallmarks of Alzheimer’s Disease
7.1.2 - Risk Factors of Alzheimer’s Disease
7.1.3 - Difficulties of Early Diagnosis of Alzheimer’s Disease
7.2 - Current Alzheimer's disease treatments and their limitations
7.2.1 - Cholinesterase Inhibitors
7.2.2 - N-methyl-D-aspartate Antagonists
7.2.3 - Treating Psychological and Behavioural Symptoms
7.2.4 - Limitations of current Alzheimer's disease treatment options
7.3.1 - Specific Neurotransmitter-based Treatments
7.3 - Emerging Treatment Options
7.3.2 - General Targets for Neurotransmitters
7.4 - Emerging NAP Therapy
7.4.1 - NAP in Providing Neuroprotection
7.4.2 - In-vitro Analysis of NAP and Neurotoxicity
7.5 - The Future of NAP Therapy in Alzheimer's Disease and Beyond
7.5.2 - Implications of NAP for Alzheimer’s Disease and Beyond
7.5.1- Limitations of NAP
7.6 - References
Acknowledgements
Appendix
Emily Mount
Niro Kalaiarasan
Junru Hu
Marsela Supriadi
Previous/next navigation
Selected Topics in Health and Disease (2019 Edition) Copyright © by Dr. Ju. All Rights Reserved.
